Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 13/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881516 | 0.92 | OPRM1 (0.43) | BCHEACHEOPRM1OPRK1OPRD1 | |
| SCHEMBL6873443 | 0.85 | OPRM1 (0.40) | BCHEACHEOPRM1OPRK1OPRD1 | |
| SCHEMBL1836555 | 0.80 | LMNA (0.47) | LMNAOPRM1OPRK1OPRD1 | |
| SCHEMBL30525531 | 0.80 | LMNA (0.47) | LMNAOPRM1OPRK1OPRD1 | |
| SCHEMBL6883353 | 0.79 | CRHR1 (0.43) | — | |
| SCHEMBL6881607 | 0.77 | NR1H2 (0.43) | BCHEACHEOPRM1OPRK1OPRD1 | |
| SCHEMBL6884492 | 0.77 | BCHE (0.43) | BCHEACHELMNA | |
| SCHEMBL6880642 | 0.77 | LMNA (0.44) | LMNAOPRM1OPRK1OPRD1 | |
| SCHEMBL6884073 | 0.77 | LMNA (0.44) | LMNAOPRM1OPRK1OPRD1 | |
| SCHEMBL6881281 | 0.77 | LMNA (0.44) | LMNAOPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242891-A1 | Production of keto acids | CAMPBELL JONATHAN (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1442009-A1 | PRODUCTION OF KETO ACIDS | Ciba SC Holding AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-6635602-B1 | Heat sensitive and pressure sensitive recording material; synthesised directly by the reaction of two derivatives of amino phenols, phthalic anhydrides, keto acids and/or diphenylamines with a phenol derivative | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-10-21 | — | — | US | disclosed |
| US-6566302-B1 | For use in heat sensitive and pressure sensitive recording materials | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-05-20 | — | — | US | disclosed |
| WO-2003037846-A1 | PRODUCTION OF KETO ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-1107972-B1 | PREPARATION PROCESS FOR MANUFACTURE AND PURIFICATION OF MIXTURES OF FLUORAN COMPOUNDS AND RECORDING MATERIAL COMPRISING SAID MIXTURES OF FLUORAN | CIBA SC HOLDING AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| EP-1115579-B1 | MONOPHASE SOLID SOLUTIONS COMPRISING A PLURALITY OF COLOUR FORMER COMPOUNDS AND PROCESS FOR THEIR PREPARATION | CIBA SC HOLDING AG (CH) | 2002-11-20 | — | — | EP | disclosed |
| EP-0853079-B1 | Production of keto acids | CIBA SC HOLDING AG (CH) | 2002-06-05 | — | — | EP | disclosed |
| US-5925787-A | Production of keto acids | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0853079-A1 | Production of keto acids | Ciba SC Holding AG (CH) | 1998-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242891-A1 | Production of keto acids | PKLR, KHK, ME1 | BCHE 3872/4885ACHE 4845/4885LMNA 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.